ORIGINAL ARTICLE
Correspondence of cytological and histopathological diagnoses in diagnostic category V of the Bethesda system: “suspicious for malignancy”
Submission date: 2015-12-01
Final revision date: 2016-02-16
Acceptance date: 2016-04-24
Publication date: 2016-05-10
Pol J Pathol 2016;67(1):24-32
KEYWORDS
TOPICS
ABSTRACT
The progress in imaging methods enables fine needle aspiration (FNA) biopsy to be performed on smaller and smaller lesions, including malignant ones (papillary microcarcinomas). The follicular variant predominates in this group, with cytological features often not permitting an unbiased interpretation. The aim of the study was to determine the degree of reliability of the “suspicious for malignancy” (SM) diagnosis in material from the Institute of Oncology in Gliwice (IO).
290 primary SM diagnoses were established from 2010 to 2015 in the IO, including the consultations. None of the patients was treated surgically after the first FNA resulting in diagnostic category V (DC V). After the second FNA 80 patients underwent surgery, after the third 58, and after subsequent FNA 10. Together, 148 surgical resections were performed.
Among 148 patients treated surgically, 111 were diagnosed with malignant lesions, which constitutes 75%. Predominantly – in 91 cases – the histopathological outcome was papillary carcinoma. The others were: 16 medullary carcinomas, 2 follicular carcinomas, and 2 poorly differentiated carcinoma cases. Moreover, 8 follicular adenomas and 28 nonneoplastic lesions were found.
The high positive predictive value (PPV = 75%) of SM diagnosis established in the IO testifies to the high reliability of this test. Diagnostic category V in FNA should be an indication for surgical treatment.
290 primary SM diagnoses were established from 2010 to 2015 in the IO, including the consultations. None of the patients was treated surgically after the first FNA resulting in diagnostic category V (DC V). After the second FNA 80 patients underwent surgery, after the third 58, and after subsequent FNA 10. Together, 148 surgical resections were performed.
Among 148 patients treated surgically, 111 were diagnosed with malignant lesions, which constitutes 75%. Predominantly – in 91 cases – the histopathological outcome was papillary carcinoma. The others were: 16 medullary carcinomas, 2 follicular carcinomas, and 2 poorly differentiated carcinoma cases. Moreover, 8 follicular adenomas and 28 nonneoplastic lesions were found.
The high positive predictive value (PPV = 75%) of SM diagnosis established in the IO testifies to the high reliability of this test. Diagnostic category V in FNA should be an indication for surgical treatment.
REFERENCES (43)
1.
Vaccarella S, Dal Maso L, Laversanne M, et al. The impact of diagnostic changes on the rise in thyroid cancer incidence:.
2.
a population-based study in selected high-resource countries. Thyroid Off J Am Thyroid Assoc 2015; 25: 1127-1136.
3.
Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ 2013; 347: f4706.
4.
Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”– screening and overdiagnosis. N Engl J Med 2014; 371: 1765-1767.
5.
Ratour J, Polivka M, Dahan H, et al. Diagnosis of follicular lesions of undetermined significance in fine-needle aspirations of thyroid nodules. J Thyroid Res 2013; 2013: 250347.
6.
Bohacek L, Milas M, Mitchell J, et al. Diagnostic accuracy of surgeon-performed ultrasound-guided fine-needle aspiration of thyroid nodules. Ann Surg Oncol 2012; 19: 45-51.
7.
La Vecchia C, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer J Int Cancer 2015; 136: 2187-2195.
8.
Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014; 140: 317-322.
9.
Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009; 115: 3801-3807.
10.
Faquin WC, Wong LQ, Afrogheh AH, et al. Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology. Cancer Cytopathol 2016; 124: 181-187.
11.
Davies L, Morris LGT, Haymart M, et al., AACE Endocrine Surgery Scientific Committee American Association Of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: The increasing incidence of thyroid cancer. Endocr Pract 2015; 21: 686-696.
13.
Dean DS, Gharib H. Fine-needle aspiration biopsy of the thyroid gland. In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al. (eds.). Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.
14.
Cibas ES, Ali SZ., NCI Thyroid FNA state of the science Conference The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol 2009; 132: 658-665.
15.
Jarząb B, Sporny S, Lange D, et al., Polish Endocrinology Society, Polish Thyroid Society, Polish Pathologic Society et al. Diagnosis and treatment of thyroid cancer – Polish guidelines. Endokrynol Pol 2010; 61: 518-568.
16.
Olson MT, Boonyaarunnate T, Altinboga AA, et al. “Suspicious for papillary thyroid carcinoma” before and after The Bethesda System for Reporting Thyroid Cytopathology: impact of standardized terminology. Acta Cytol 2014; 58: 15-22.
17.
Renshaw AA. Should “atypical follicular cells” in thyroid fine-needle aspirates be subclassified? Cancer Cytopathol 2010; 118: 186-189.
18.
Bongiovanni M, Spitale A, Faquin WC, et al. The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol 2012; 56: 333-339.
19.
Nayar R, Ivanovic M. The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer 2009; 117: 195-202.
20.
Mondal SK, Sinha S, Basak B, et al. The Bethesda system for reporting thyroid fine needle aspirates: A cytologic study with histologic follow-up. J Cytol Indian Acad Cytol 2013; 30: 94-99.
21.
Tepeoğlu M, Bilezikçi B, Bayraktar SG. A histological assessment of the Bethesda system for reporting thyroid cytopathology (2010) abnormal categories: a series of 219 consecutive cases. Cytopathology 2014; 25: 39-44.
22.
Ho AS, Sarti EE, Jain KS, et al. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid 2014; 24: 832-839.
23.
Vanderlaan PA, Krane JF, Cibas ES. The frequency of “atypia of undetermined significance” interpretations for thyroid fine-needle aspirations is negatively correlated with histologically proven malignant outcomes. Acta Cytol 2011; 55: 512-517.
24.
VanderLaan PA, Marqusee E, Krane JF. Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated fna be the preferred initial approach? Am J Clin Pathol 2011; 135: 770-775.
25.
Smith M, Pantanowitz L, Khalbuss WE, et al. Indeterminate pediatric thyroid fine needle aspirations: a study of 68 cases. Acta Cytol 2013; 57: 341-348.
26.
Al-Abbadi MA, Shareef SQ, Ali JA, et al. Application of the Bethesda System for Reporting Thyroid Cytopathology in the Eastern Province of Saudi Arabia: phase I pilot retrospective analysis. Acta Cytol 2013; 57: 481-488.
27.
Olson MT, Clark DP, Erozan YS, et al. Spectrum of risk of malignancy in subcategories of “atypia of undetermined significance”. Acta Cytol 2011; 55: 518-525.
28.
Harvey AM, Mody DR, Amrikachi M. Thyroid fine-needle aspiration reporting rates and outcomes before and after Bethesda implementation within a combined academic and community hospital system. Arch Pathol Lab Med 2013; 137: 1664-1668.
29.
Theoharis C, Adeniran AJ, Roman S, et al. The impact of implementing The Bethesda System for reporting of thyroid FNA at an academic center. Diagn Cytopathol 2013; 41: 858-863.
30.
Jo VY, Stelow EB, Dustin SM, et al. Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology. Am.
32.
Bongiovanni M, Crippa S, Baloch Z, et al. Comparison of 5-tiered and 6-tiered diagnostic systems for the reporting of thyroid cytopathology: a multi-institutional study. Cancer Cytopathol 2012; 120: 117-125.
33.
Srbova L, Gabalec F, Ryska A, et al. Results of retrospective classification of thyroid FNAs according to the Bethesda system: would this have improved accuracy? Cytopathology 2015; 26: 231-237.
34.
Dincer N, Balci S, Yazgan A, et al. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology. Cytopathology 2013; 24: 385-390.
35.
Chen H, Izevbaye I, Chen F, et al. Recent advances in follicular variant of papillary thyroid carcinoma. NAJ Med Sci 2012; 5: 212-216.
36.
Strickland KC, Howitt BE, Marqusee E, et al. The Impact of noninvasive follicular variant of papillary thyroid carcinoma on rates of malignancy for fine-needle aspiration diagnostic categories. Thyroid 2015; 25: 987-992.
37.
Giordano TJ, Beaudenon-Huibregtse S, Shinde R, et al. Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens. Hum Pathol 2014; 45: 1339-1347.
38.
Damiani D, Suciu V, Vielh P. Cytopathology of follicular cell nodules.. Endocr Pathol 2015; 26: 286-290.
39.
Baloch ZW, LiVolsi VA. Cytologic and architectural mimics of papillary thyroid carcinoma. Diagnostic challenges in fine-needle aspiration and surgical pathology specimens. Am J Clin Pathol 2006; 125 Suppl: S135-S144.
40.
Cheung CC, Boerner SL, MacMillan CM, et al. Hyalinizing trabecular tumor of the thyroid: a variant of papillary carcinoma proved by molecular genetics. Am J Surg Pathol 2000; 24: 1622-1626.
41.
Boerner SL, Asa SL. Hyalinizing trabecular tumor of the thyroid gland: much ado about nothing? Am J Clin Pathol 2004; 122: 495-496.
42.
Papotti M, Volante M, Giuliano A, et al. RET/PTC activation in hyalinizing trabecular tumors of the thyroid. Am J Surg Pathol 2000; 24: 1615-1621.
43.
Bugalho MJM, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol 2005; 91: 56-60.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
